Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole

Venetoclax requires a 75% dose reduction when coadministered with voriconazole. In a 10-year historical cohort of treatment with venetoclax, we did not observe a worse hematologic outcome in patients who received voriconazole prophylaxis versus those who did not. Subtherapeutic voriconazole levels a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Victoria G, Tang, Kenny, Kumar, Deepali, Rotstein, Coleman, Chow, Signy, Chan, Steven M, Husain, Shahid, Hosseini-Moghaddam, Seyed M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064263/
https://www.ncbi.nlm.nih.gov/pubmed/37008567
http://dx.doi.org/10.1093/ofid/ofad134
Descripción
Sumario:Venetoclax requires a 75% dose reduction when coadministered with voriconazole. In a 10-year historical cohort of treatment with venetoclax, we did not observe a worse hematologic outcome in patients who received voriconazole prophylaxis versus those who did not. Subtherapeutic voriconazole levels and a triazole exposure history may contribute to breakthrough invasive fungal infection.

Ejemplares similares